Table 5b.
Comparison of anti-RBD-IgG1 and IgG4·GMTs for all formulation C&B cohorts from phase-1/2 study and formulation E from phase-2 study.
| Formulation | N | IgG1 Titer |
IgG4 Titer |
IgG1/IgG4 RatioGMR post vaccination | ||||
|---|---|---|---|---|---|---|---|---|
| D-0 GMT | D-56 or D-42 | GMFR | D-0 GMT | D-56 or D-42 | GMFR | |||
| GMT | GMT | |||||||
| C | 89 | 65 | 1884 (D56) | 28·92 | 27 | 50 (D56) | 1·81 | 38·0 |
| B | 90 | 74 | 2940 (D56) | 39·7 | 31 | 76 (D56) | 2·48 | 37·1 |
| E | 98 | 126 | 7167 (D42) | 56·89 | 41 | 95 (D42) | 2·32 | 75·4 |
N:number; D-0: Day0; D-42: Day42; D-56: Day56; GMT: Geometric mean titer; GMFR: Geometric mean fold rise; IgG: Immunoglobulin G; GMR: geometric mean ratio.
Note: GMFR for each formulation cohort is calculated from the Geometric Mean for the Fold Rise in titer at Day56 or Day42 vs Day0 time-point for each cohort· Geometric Mean Ratio was calculated for IgG1 to IgG4 titers post vaccination for the three cohorts.